Project: A novel, topical drug for treatment of diabetic foot infections (DFI)

We want to provide solid evidence of the clinical efficacy of LTX-109 in treatment of infections in diabetic foot ulcers, which is a debilitating medical condition with a large unmet need. The effect of this novel, topical antimicrobial drug will be demonstrated in a Phase II proof-of-concept study in patients with mild diabetic foot ulcers. The drug development will be accomplished in collaboration with other European SMEs.

Acronym	CureDFI (Reference Number: 9146)
Duration	01/10/2014 - 01/03/2016
Project Topic	Biological Sciences / Technologies
Network	Eurostars 2
Call	Eurostars Cut-Off 1

Project partner

Number	Name	Role	Country
19687	Lytix Biopharma AS	Coordinator	Norway
19688	Smerud Medical Research UK Ltd	Partner	United Kingdom
19689	MedPharm Ltd	Partner	United Kingdom
19690	CTC Clinical Trial Consultants AB	Partner	Sweden